Drug Trial Radar · NCT05875948
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
95
Planned (sponsor's estimate)
Start
Jun 30, 2023
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- River 2 Renal Corp.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
Conditions
- Hepatorenal Syndrome
- Acute Kidney Injury
Interventions
R2R01Drug
Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.
TerlipressinDrug
In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL). In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Evaluation Criteria - Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug to 30 days post last dose
- Safety Evaluation Criteria - Change in WeightTime frame: Change from screening through Day 30
- Safety Evaluation Criteria - Vital Signs - Respiration RateTime frame: Change from screening through Day 30
- Safety Evaluation Criteria - Vital Signs - Body TemperatureTime frame: Change from screening through Day 30
- Safety Evaluation Criteria - Vital Signs - Continuous pulse oximetry (SpO2)Time frame: Change from baseline through Day 30
- Safety Evaluation Criteria - Vital Signs - Systolic Blood Pressure (SBP)Time frame: Change from screening through Day 30
- Safety Evaluation Criteria - Vital Signs - Diastolic Blood pressure (DBP)Time frame: Change from screening through Day 30
- Safety Evaluation Criteria - Vital Signs - Heart Rate (HR)Time frame: Change from screening through Day 30
- Safety Evaluation Criteria - ECGs - PR intervalTime frame: Change from screening to Day 14 or hospital discharge
- Safety Evaluation Criteria - ECGs - RR intervalTime frame: Change from screening to Day 14 or hospital discharge
- Safety Evaluation Criteria - ECGs - QRS durationTime frame: Change from screening to Day 14 or hospital discharge
- Safety Evaluation Criteria - ECGs - QT intervalTime frame: Change from screening to Day 14 or hospital discharge
- Safety Evaluation Criteria - ECGs - QTcF intervalTime frame: Change from screening to Day 14 or hospital discharge
- Safety Evaluation Criteria - ECGs - QTcB intervalTime frame: Change from screening to Day 14 or hospital discharge
- The incidence of RespondersTime frame: 90 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
California Pacific Medical Center
San Francisco, California · Not yet recruiting
Piedmont Healthcare, Inc
Atlanta, Georgia · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Not yet recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Baylor Scott and White All Saints Medical Center
Fort Worth, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.